Funded Projects › HORIZON
PANVIPREP · Developing broad-spectrum antiviral drugs for pandemic preparedness
Antiviral drugs will be key in the management of future virus outbreaks. For each virus family with epidemic/pandemic potential, stockpiles of potent drugs are needed that can be deployed when a new pathogen emerges. Such broader-acting drugs (targeting conserved viral functions) are needed as of “day one” of an outbreak, for treatment and prophylaxis (e.g., in HCW and frail patients). In combination with quarantine measures, such drugs will delay (global) spread, allowing time for vaccine-development. Since the 2003 SARS outbreak, PANVIPREP’s core partners have successfully collaborated in leading European antiviral drug research projects. This provides a solid scientific basis in combination with translational drug discovery expertise. The team includes virologists, biochemists, structural biologists, medicinal chemists and pharmacokinetics experts. Previously developed know-how and toolboxes will be a major asset to achieve immediate impact. PANVIPREP aims to greatly expand the antiviral portfolio and identify novel druggable targets of high-risk RNA viruses. Hits will be identified through (i) phenotypic antiviral screening of compound libraries (ii) structure-based drug design, (iii) in silico screening, supported by the latest machine-learning methods. We will deliver 25 to 50 high-quality, broad(er)-spectrum (pan-genus/pan-family) hit molecules/hit series. Two of these will be developed to the early lead stage, including proof of concept in animal infection models. Remaining hits will serve as chemical tool-compounds to explore mechanisms of action thereby identifying novel druggable targets in RNA virus replication. This in turn will accelerate target-based drug design efforts. The workflow will integrate best practices in antiviral drug discovery with a range of methodological innovations, including AI-based methods, thus renovating and accelerating the antiviral hit discovery pipeline future use and contributing to pandemic preparedness.
Consortium · 17 organisations
ACADEMISCH ZIEKENHUIS LEIDEN
NL · €1,204,305
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
FR
EPITHELIX SARL
CH
JIHOCESKA UNIVERZITA V CESKYCH BUDEJOVICICH
CZ · €250,000
VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE
CZ · €450,000
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
ES · €458,083
Zafiro Business Solutions Korlatolt Felelossegu Tarsasag
HU · €167,000
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
DE · €550,102
EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT
CH
EIDGENOESSISCHES DEPARTEMENT DES INNERN
CH
CENTRUM VOOR INNOVATIE EN STIMULATIE VAN MEDICIJNONTWIKKELING LEUVEN VZW
BE
UNIVERSITE D'AIX MARSEILLE
FR · €1,147,525
UNIVERSITEIT UTRECHT
NL · €535,000
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
FR
KATHOLIEKE UNIVERSITEIT LEUVEN
BE · €2,588,546
UNIVERSITAET zu LUEBECK
DE · €250,000
JANSSEN PHARMACEUTICA NV
BE · €398,735
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.